Dx Deals: Quest and Labcorp Move beyond Laboratory Testing
Both companies have made recent moves to diversify further.
Both companies have made recent moves to diversify further.
While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.
As is usual at this time of year, deals in the diagnostics industry were up, both in terms of volume and value.
Here are what G2 Intelligence considers the three most significant deals announced in the period from late August to early September.
A strategic partnership with Google enables more accurate whole genome sequencing with machine learning.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
The national retailer recently signed a deal with Simple HealthKit to provide Walmart customers online access to at-home diagnostic test kits.
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
Genomics software developer Allelica to collaborate with Taiwanese precision medicine firm to develop a multi-ancestry breast cancer test.